An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trialFlorence Ader, Marion Noret, Julien Poissy et al.|medRxiv|2022Cited by 1